HRA Pharma

F7TG2202 is a recombinant Coagulation Factor VIIa program sponsored by Laboratoire HRA Pharma for the treatment of hemophilia. The program represents a monoclonal antibody modality approach to hemophilia management, though specific mechanism of action details remain undisclosed. The program was in Phase 3 development but has been terminated as of the latest milestone dated 9 July 2025. No partner or licensing arrangement is currently disclosed. The termination represents a strategic shift away from this particular development pathway, though the rationale for discontinuation has not been publicly detailed. The competitive landscape for hemophilia includes multiple approved therapies spanning coagulation factor replacement, gene therapy, and bypass agents, indicating a mature but evolving market with diverse treatment options.

The program was associated with clinical trial NCT05695391, which appears to have been the pivotal Phase 3 study. Prior to termination, the recombinant Factor VIIa candidate had been evaluated across multiple clinical trials in China registered under the NMPA, spanning NCT01084265 through NCT03095079. The termination of F7TG2202 in mid-2025 suggests that efficacy, safety, or commercial viability concerns may have prompted the decision to discontinue further development. No projected peak sales, regulatory filing dates, or expected approval timelines were disclosed prior to termination.

Hemophilia remains a significant unmet medical need despite the availability of multiple approved therapies. While Factor VIII and Factor IX replacement products dominate the market, the disease continues to present challenges including inhibitor development, frequent dosing requirements, and variable patient response. The recombinant Factor VIIa approach, if successful, could have offered an alternative mechanism for patients with specific hemophilia subtypes or those with inhibitors to conventional therapies.

The termination of F7TG2202 reflects the competitive pressures and high bar for approval in the hemophilia space. Approved competitors include ADVATE (Factor VIII), ROCTAVIAN (gene therapy with Factor IX), HEMLIBRA (bispecific antibody), and multiple thrombopoietin receptor agonists. The monoclonal antibody modality selected for F7TG2202 was differentiated from traditional protein replacement, potentially offering improved pharmacokinetics or reduced immunogenicity. However, the termination suggests that clinical or commercial data did not support continuation.

The patient population for hemophilia includes both congenital and acquired forms, with varying severity and inhibitor status. Market relevance depends on addressing unmet needs in difficult-to-treat populations, including those with inhibitors or poor venous access. The discontinuation of F7TG2202 may redirect resources within HRA Pharma's hemostasis portfolio or signal market saturation in certain hemophilia segments.

F7TG2202 is classified as a monoclonal antibody (mab modality) targeting coagulation pathways for hemophilia treatment. The program name indicates a recombinant Factor VIIa-based approach, though the precise molecular target and mechanism of action remain undisclosed in available sources.

• Drug Class: Recombinant coagulation factor; monoclonal antibody modality
• Mechanism of Action: Not yet disclosed
• Molecular Target: Not yet disclosed
• Route of Administration: Not yet disclosed
• Therapeutic Class: Blood and blood forming organs (B02)
• Related Approved Therapies: ADVATE (Factor VIII), ROCTAVIAN (Factor IX gene therapy), HEMLIBRA (bispecific antibody), NOVOTHIRTEEN (Factor XIII)
• Patent Status: Not yet disclosed
• First Approval: Program terminated; no approval achieved

The monoclonal antibody modality represents a departure from traditional recombinant protein replacement, potentially offering advantages in stability, immunogenicity, or dosing frequency. However, specific differentiation from competitors remains undisclosed.

FDA (United States): Regulatory status not yet disclosed.

EMA (European Union): Regulatory status not yet disclosed for F7TG2202. Note: VONCENTO (human coagulation factor VIII/von Willebrand factor, CSL Behring) was approved by EMA on 17 December 2024 (EMEA/H/C/002493), representing a related hemostasis therapy.

NMPA (China): Recombinant Factor VIIa candidate was in clinical trials in China, with multiple trial registrations (NCT01084265, NCT01310478, NCT01551628, NCT01733589, NCT01915134, NCT01922193, NCT01941576, NCT02283489, NCT02764671, NCT03095079) indicating prior development activity in the Chinese market.

PMDA (Japan): Regulatory status not yet disclosed.

Program Status: F7TG2202 was terminated on 9 July 2025 prior to any regulatory filing or approval. No regulatory submissions are known to have been made.

Strategic Implications: The termination of F7TG2202 in July 2025 represents a significant strategic decision by Laboratoire HRA Pharma to discontinue a Phase 3 hemophilia program. This suggests that interim efficacy, safety data, or commercial projections did not justify continued investment relative to the competitive landscape and regulatory approval bar. The decision may reflect challenges in differentiating a monoclonal antibody approach in a market dominated by established Factor VIII/IX replacements and emerging gene therapies.

Competitive Implications: The termination removes a potential alternative mechanism from the hemophilia market. Competitors including Takeda (ADVATE), BioMarin (ROCTAVIAN), and others with approved therapies face no new competitive threat from F7TG2202. The crowded competitive space, with 12+ approved hemostasis therapies listed, likely contributed to HRA Pharma's decision to reallocate resources.

Future Catalysts: No future development milestones are expected for F7TG2202. HRA Pharma may redirect hemostasis research efforts toward other indications or mechanisms. The company's hemostasis portfolio strategy will be clarified through future program announcements or investor communications.

Expected Milestones: None anticipated for F7TG2202. Program termination is final unless HRA Pharma announces revival, which would require disclosure of new clinical or commercial rationale.